Close
Smartlab Europe
Achema middle east

Clinical Trials

Oxford Covid-19 vaccine: Serum Institute begins clinical trial in India

Serum Institute of India’s trial for ‘Covishield’ vaccine developed by the University of Oxford started with the first patients screened by Bharati Vidyapeeth Deemed University (BVDU) Medical College and Hospital in Pune. We have screened some patients. Tomorrow, we will...

Australian COVID-19 vaccine shows promising results in animal trials

A COVID-19 vaccine candidate being developed by Australia’s University of Queensland has shown “positive” results against the novel coronavirus in preclinical tests, raising hopes for its potential effectiveness and manufacturability, the varsity said on Wednesday. According to the yet-to-be published...

Trialbee Partners with Clinerion for Expanded Access to Global Real-World Data to Accelerate Patient Recruitment for Clinical Trials

Trialbee, a leading global technology provider for patient matching and engagement in clinical trials, announced a partnership with Clinerion, a worldwide leader in medical data informatics with a global research network comprised of 30.2 million patients online across 69...

AstraZeneca Phase I clinical trial initiated for COVID-19 monoclonal antibody

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19. The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics...

BMS Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Bristol Myers Squibb announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine...

Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875

Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) announced that the first cancer patients have started treatment with its investigational antibody-drug conjugate (ADC) SYD1875. The First-in-Human Dose-Escalation and Expansion Study with the Antibody-Drug Conjugate SYD1875 will evaluate the safety, pharmacokinetics and preliminary...

Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer

Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »